During the past decade, Liver Cancer Institute conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Liver Cancer Institute" are "Hepatocellular Carcinoma" (5 trials) and "Recurrence" (1 trials). Many other conditions were trialed in "Liver Cancer Institute" in a lesser frequency.

Most popular intervention types in "Liver Cancer Institute" are "Drug" (5 trials). Other intervention types were less common.

The name of intervention was led by "Aspirin" (1 trials), "Lamivudine" (1 trials), "Sorafenib and Zoledronic Acid" (1 trials), "TACE" (1 trials) and "Thalidomide" (1 trials). Other intervention names were less common.

The vast majority of trials in "Liver Cancer Institute" are 5 trials for "All" genders.

Currently, there are NaN active trials in "Liver Cancer Institute". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Liver Cancer Institute, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Liver Cancer Institute, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".